GlassScriptPhysician profile
James H Bui
NPI 1477631182
$11,151.17
in general payments reported to CMS, 2019-2025
37 companies · $491 in 2025
The $491 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,560 · 2020: $569 · 2021: $1,063 · 2022: $1,437 · 2023: $1,608 · 2024: $1,423 · 2025: $491.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,523.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,522.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,382.05 | 2019-2025 | Datroway |
| Genentech USA, INC. | $1,287.01 | 2019-2025 | Lunsumio, Tecentriq, Xolair |
| Amgen INC. | $765.09 | 2019-2025 | Kyprolis, Evenity, Blincyto |
| Neurocrine Biosciences, INC. | $761.99 | 2019-2024 | Ingrezza |
| Incyte Corporation | $756.33 | 2019-2023 | Jakafi |
| Biogen, INC. | $597.16 | 2019-2025 | Skyclarys, Spinraza |
| Gilead Sciences, INC. | $520.28 | 2019-2023 | Epclusa |
| Genzyme Corporation | $484.30 | 2019-2024 | |
| Eisai INC. | $357.83 | 2022-2024 | |
| Beigene USA, INC. | $352.30 | 2023-2024 | Brukinsa |
| Teva Pharmaceuticals USA, INC. | $348.50 | 2019-2024 | Uzedy |
| Novartis Pharmaceuticals Corporation | $311.38 | 2019 | |
| Abbott Laboratories | $246.02 | 2024-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $225.40 | 2020-2023 | Arexvy |
| Pfizer INC. | $198.99 | 2024 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $198.39 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $195.53 | 2019-2024 | Hyqvia |
| Seagen INC. | $173.76 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $167.49 | 2019 | |
| Amarin Pharma, INC. | $124.99 | 2019 | |
| Epizyme, INC. | $123.50 | 2021 | |
| Agios Pharmaceuticals, INC. | $122.31 | 2024 | Pyrukynd |
| Sunovion Pharmaceuticals INC. | $121.35 | 2019 | |
| Clovis Oncology, INC. | $120.65 | 2019 | |
| Celgene Corporation | $109.73 | 2019 | |
| Redhill Biopharma INC. | $108.07 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $107.74 | 2019 | |
| Daiichi Sankyo INC. | $102.73 | 2021 | |
| Jazz Pharmaceuticals INC. | $100.50 | 2019 | |
| Portola Pharmaceuticals, LLC | $99.57 | 2020 | |
| Alexion Pharmaceuticals, INC. | $98.68 | 2019 | |
| Janssen Biotech, INC. | $91.02 | 2019 | |
| Btg International INC. | $88.29 | 2019 | |
| Astellas Pharma US INC | $83.61 | 2019 | |
| Janssen Pharmaceuticals, INC | $82.37 | 2019 | |
| Novo Nordisk INC | $73.70 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Bui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.